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Abstract: Boron neutron capture therapy (BNCT) requires pharmaceutical innovations
and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future.
Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT
against head and neck (H&N) cancers. H&N cancer appears to be a suitable target for BPA-BNCT,
because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid
transporters responsible for BPA uptake, are elevated in most cases of H&N cancer. However,
in other types of cancer including malignant brain tumors, LAT1 is not always highly expressed.
To expand the possibility of BNCT for these cases, we previously developed poly-arginine peptide
(polyR)-conjugated mercaptoundecahydrododecaborate (BSH). PolyR confers the cell membrane
permeability and tumor selectivity of BSH. However, the molecular determinants for the properties
are not fully understood. In this present study, we have identified the cluster of differentiation 44
(CD44) protein and translational machinery proteins as a major cell surface target and intracellular
targets of BSH-polyR, respectively. CD44, also known as a stem cell-associated maker in various
types of cancer, is required for the cellular uptake of polyR-conjugated molecules. We showed that
BSH-polyR was predominantly delivered to a CD44High cell population of cancer cells. Once delivered,
BSH-polyR interacted with the translational machinery components, including the initiation factors,
termination factors, and poly(A)-biding protein (PABP). As a proof of principle, we performed
BSH-polyR-based BNCT against glioma stem-like cells and revealed that BSH-polyR successfully
induced BNCT-dependent cell death specifically in CD44High cells. Bioinformatics analysis indicated
that BSH-polyR would be suitable for certain types of malignant tumors. Our results shed light on
the biochemical properties of BSH-polyR, which may further contribute to the therapeutic optimization
of BSH-BNCT in the future.
Keywords: boron neutron capture therapy (BNCT); BSH-polyR; CD44; translational machinery;
bioinformatics
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1. Introduction
Boron neutron capture therapy (BNCT) is a cancer therapeutic modality that utilizes a combination
of boron 10B delivery and epithermal neutron irradiation. It results in a spatially and temporally
controlled intracellular 10B nuclear reaction, which generates high-energy alpha particles [1–3].
To achieve a safe and efficient therapeutic response, high specificity and selectivity of the 10B
distribution to cancer cells is required.
Current BNCT clinical research primarily utilizes two kinds of boron agents, 4-borono-L-phenylalanine
(BPA) and mercaptoundecahydrododecaborate (BSH), whose pharmacokinetics are different. BPA is
a 10B-derivative of tyrosine/phenylalanine (C9H12BNO4) and is taken up via the L-type amino acid
transporter 2 (LAT2) and LAT1 [4,5]. Although these transporters are ubiquitously expressed in the human
body, BPA-BNCT has been used to treat several types of cancer, such as head and neck (H&N) cancer
and malignant brain tumors [6]. Indeed, BPA was approved by the Ministry of Health, Labour and Welfare
of Japan as a boron delivery agent for BNCT of advanced or recurrent H&N cancers in Japan on March
25, 2020.
BSH as well as its derivative carboranes are other candidate boron delivery agents for BNCT. BSH
has a high content of boron atoms per single molecule ((B12H11SH)Na2), but it has a critical disadvantage
for clinical usage, namely, poor cellular uptake. In the history of boron agent development, BSH
preceded BPA, as BSH was applied to the clinical research of BNCT against malignant brain tumors in
the 1960–1970s [7], while BPA has been used for melanoma since the 1980s [8]. However, BSH was soon
replaced by BPA, because the clinical outcomes in brain tumor patients were not as good, due to its
poor cellular uptake. In 2009, Kawabata et al. reported that a modified BNCT protocol in combination
with BPA and BSH with X-ray irradiation significantly improved the median survival time (MST) of
malignant brain tumor patients [9]. This result indicates that BSH could pass through vulnerable tumor
vessels from the blood into tumor tissue (in other words, by an enhanced permeability and retention
(EPR) effect).
To expand the possibility of BSH usage in BNCT, numerous studies developing cell-permeable
compounds of BSH or carborane were performed. For example, Kirihata and his colleagues
recently developed a Kojic acid (KA)-BSH and showed that KA-BSH-BNCT successfully improved
survival in a glioma xenograft rat model [10]. Matsumura and his colleagues developed
a α-D-mannopyranoside-conjugated closo-dodecarborate compound and demonstrated longer
tumor retention compared to BSH and BPA [11]. Hosmane et al. developed carborane-appended
5-thio-D-glucopyranose derivatives [12] and Nido-carboranyl levodopa [13], which further expanded
the possibility of carboranes.
We previously developed poly arginine (polyR)-conjugated BSH, which could successfully deliver
BSH into cancer cells both in vitro and in vivo [14]. Generally, cell-penetrating peptides (CPPs), such
as polyR and human immunodeficiency virus (HIV)-derived trans-activator of transcription protein
(TAT) peptides consist of serial amino acid sequences of lysine (K) or arginine (R), whose charge is
positive [15]. CPPs allow proteins, nucleotides, and small molecules to penetrate the plasma membrane
of various kinds of cells in a macropinocytosis-dependent mechanism [16].
Although the molecular determinants of the cell-penetrating properties of CPPs are not
fully understood, previous studies identified several cell-surface targets that were required for
the membrane-permeability of certain types of CPP. For example, Tanaka et al. showed that arginine
12-mer peptide (R12), but not 8-mer bound to C-X-C chemokine receptor type 4 (CXCR4), further
stimulated the macropinocytosis of the R12-conjugated molecule [17]. The intracellular targets for
both CPP and BSH are currently not well defined. In the BNCT research field, such information would
be helpful to develop new boron delivery agents, since we might be able to predict the efficiency of
boron delivery and the efficacy of BNCT by combining this with the information of protein expression
profiles of target cancer cells. The purpose of this report is to present experimental evidence supporting
this concept.
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2. Materials and Methods
2.1. Cell Culture and Lentivirus Preparation
Human glioma cell lines U87MG and U251MG, human breast cancer cell lines MCF7
and MDA-MB-231, human pancreatic cancer cell lines CFPAC1 and PANC1, and murine mammary
gland cell line NMuMG, were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (FUJIFILM
Wako Pure Chemical Corporation, Osaka, Japan) with 10% fetal bovine serum (FBS) (Corning Inc.,
Corning, NY, USA) and penicillin/streptomycin/L-glutamine (Fujifilm-Wako, Japan) as previously
described [18]. U87MG, MDA-MB-231, CFPAC-1, PANC-1, and NMuMG were obtained from
the American Type Culture Collection (ATCC, Manassas, VA, USA) (catalogue number: HTB-14,
HTB-26, CRL-1918, CRL-1469, and CRL-1636, respectively). U251MG and MCF7 were obtained from
the Japanese Collection of Research Bioresources Cell Bank (JCRB, Ibaraki, Japan) (catalogue number:
IFO50288 and JCRB0134, respectively).
The human glioblastoma stem-like cell lines MGG4, MGG8, MGG18, and MGG23 were established
and kindly provided by Dr. Hiroaki Wakimoto (Massachusetts General Hospital). Wakimoto
and his colleagues investigated the molecular properties of these cells and characterized MGG4
as “endothelial proliferation”, MGG8 as “primitive neuroectodermal tumor (PNET)-like component”,
MGG18 as “giant cell glioblastoma multiforme (GBM)”, and MGG23 as “gemistocytic GBM” [19].
These cells were cultured in neurobasal medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA)
with 1 × B-27 supplement (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1 ×N-2 supplement
(Thermo Fisher Scientific, Inc., Waltham, MA, USA), and penicillin/streptomycin, or DMEM/F-12
medium (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) supplemented with bovine
serum albumin, insulin, and transferrin (BIT) 9500 (STEMCELL Technologies, Vancouver, Canada)
and penicillin/streptomycin/L-glutamine.
For knockdown experiments, we transfected pLKO.1-puro-shRNA vector (10 µg), psPAX2 (7.5 µg),
and pMD2.G (2.5 µg) with TransIT-LT1 (Takara Bio Inc., Kusatsu, Japan) into human embryonic kidney
293FT cells cultured in a 10 cm dish. All parental plasmids were obtained from Addgene (Watertown,
MA, USA) (pLKO.1 puro; #8453, psPAX2; #12260, pMD2.G; #12259). After 16 h of transfection,
the medium was switched to DMEM with 10% FBS and cultured for 48 h. Then, virus-containing
culture supernatant was filtered with a 0.45 µm pore size polysulfone membrane (S-2504) (KURABO
INDUSTRIES LTD., Osaka, Japan). For the infection of cancer cells cultured on a 60 mm dish, we
added 1 mL of virus-containing culture supernatant and 4 mL of DMEM with 10% FBS. After 2 days of
infection, the cells were re-seeded for analysis.
For transformation of the NMuMG cells, we prepared virus particles of pTomo-HRas/shRNA-p53
(Vector plasmid was a kind gift from Dr. Dinorah Morvinski, Tel Aviv University), pTomo (Addgene,
#26291), FUW-tetO-wtYAP (Addgene, #84009), and FUdeltaGW-rtTA (Addgene, #19780), and infected
cells in the same manner as written above. After the infection of pTomo viruses (pTomo-HRas/shRNA-p53
was used for malignant transformation, with pTomo for a negative control), the cells were further treated
with adenovirus harboring Cre recombinase (cat#ADV-005) (Cell Biolabs Inc., San Diego, CA, USA),
to activate the HRas expression cassette. The transformation was confirmed by the acquisition of
the spheroid-forming capacity and morphological change (epithelial to spindle form).
2.2. Sequence of shRNA and Oligonucleotides
The sequences of the shRNA targeting human cluster of differentiation 44 (CD44)#1:
5′-GGACCAATTACCATAACTATTCTCGAGAATAGTTATGGTAATTGGTCC-3′, human CD44#2:
5′-CCTCCCAGTATGACACATATTCTCGAGAATATGTGTCATACTGGGAGG-3′, and negative control:
5′-CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG-3′ (Addgene, #1864).
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2.3. Boron Compounds and Boron Content Measurement
BSH and BSH-polyR were kindly provided to us by Dr. Hideki Matsui (Okayama University). BSH
was purchased from Katchem (Prague, Czech Republic), and BSH-polyR was synthesized at GlyTech, Inc.
(Kyoto, Japan) with thiol-maleimide coupling between BSH and the peptide (Figure 1A) as previously
reported [20]. To measure the 10B concentration in cells, the cells were washed with phosphate-buffered
saline (PBS) twice, followed by dissolution in HNO3. After filtration (F2513-16) (Thermo Fisher
Scientific, Inc., Waltham, MA, USA), the 10B concentration was measured by inductively coupled
plasma-atomic emission spectrometry (ICP-AES, Vista Pro) (Seiko Instruments Inc., Chiba, Japan)
as previously reported [21] or inductively coupled plasma-mass spectrometry (ICP-MS, 7500cx) (Agilent
Technologies Inc., Santa Clara, CA, USA).
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Figure 1. T e ll l r uptake of poly-arginine peptide mercaptoundecahydr odecaborate
(BSH-polyR) cor elates with the expression profile of cl st f iff re ti ti . ) e e of
BSH-11R. (B) BSH-11R, but not BSH, can penetrate the plasma membrane of U251MG cells. (C) BSH-11R
efficiently penetra es th cellular m mbrane of U87MG, U251MG, MDA-MB-231, and PANC1 cells, but
not M F7 and CFPAC1. (D) The expression profil of CD44 is corre ated with the effic cy of BSH-11R.
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2.4. Immunomagnetic Positive Selection of BSH-11R-Binding Cells
The immunomagnetic separation of BHS-polyR-binding cells was performed using an EasySep
“Do-It-Yourself” positive selection kit (STEMCELL Technologies, Vancouver, BC, Canada) according
to the manufacturer’s instruction. To label the cells with BSH-11R, the transformed NMuMG cells
were separated with DMEM containing 5 mM ethylenediaminetetraacetic acid (EDTA) and washed
with PBS, and then incubated in DMEM with 20 µM of BSH-11R at room temperature for 10 min.
Then, the cells (1 × 108/mL) were incubated with EasySep RapidSphere magnetic beads conjugated
with anti-BSH antibody at room temperature for 30 min. The beads were washed with PBS three
times with the EasySep magnet. The positively separated cells and unbound cells were harvested
as “Positive” and “Negative” samples, respectively, and they were analyzed by Western blotting or
a sphere formation assay.
2.5. Immunofluorescent Analysis and Proximity Ligation Assay
The immunostaining of cells was performed as previously described [22] with brief modifications.
The cells were fixed with 4% paraformaldehyde (PFA) for 15 min, permeated with 0.05% Triton X-100 for
10 min, and blocked with 5% goat serum. Then, the samples were incubated with primary antibodies
for 16 h at 4 ◦C and secondary antibodies for 1 h at room temperature. Primary antibodies against
CD44 were purchased from Abcam (Cambridge, UK) (ab157107). Antibodies against the BSH molecule
(clone#: 36-2H or 38-5C) were developed by ITM Co., Ltd. (Nagano, Japan). Secondary antibodies
against murine or rabbit immunoglobulin G (IgG), labeled with Alexa fluorophores, were obtained
from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). After immunostaining, the samples were
mounted with ProLong Diamond Antifade Mountant with/without 4′,6-diamidino-2-phenylindole
(DAPI) (Thermo Fisher Scientific, Inc., Waltham, MA, USA).
A proximity ligation assay (PLA) was performed with Duolink PLA technology (Sigma-Aldrich
Co. LLC, St. Louis, MO, USA). Briefly, after fixation with 4% PFA, the cells were incubated with Duolink
Blocking Solution for 1 h at 37 ◦C and mouse anti-BSH antibody and rabbit anti-CD44 antibody for 16 h
at 4 ◦C. Then, the samples were washed with 1x PBS three times and incubated with PLUS and MINUS
PLA probes for 1 h at 37 ◦C. To detect the Duolink signals, the Duolink ligation and amplification kit
was used.
Immunofluorescent and Duolink images were obtained using a confocal laser scanning microscope
LSM780 (Carl Zeiss AG, Oberkochen, Germany).
2.6. Western Blotting
Western blotting was performed as previously described [23]. The cells were lysed in cell
lysis buffer (20 mM Tris-HCl (pH =7.5), 150 mM NaCl, 1 mM EDTA, 1 mM Na2EGTA (ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid), 0.5% Triton X-100) supplemented with
cOmplete Protease Inhibitor Cocktail (Sigma-Aldrich Co. LLC, St. Louis, MO, USA), and PhosSTOP
phosphatase inhibitor cocktail (Sigma-Aldrich Co. LLC, St. Louis, MO, USA). After sonication
and centrifugation (15,000 rpm, 4 ◦C, 10 min), the protein concentration of the supernatants was
measured using a bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Inc., Waltham, MA,
USA). The supernatants were added to 1/3 volume of 4x SDS sample buffer (240 mM Tris-HCl (pH=6.8),
8% sodium dodecyl sulfate (SDS), 40% glycerol, 0.1% bromophenol blue, 20% 2-mercaptoethanol)
and boiled at 95 ◦C for 5 min. Then, the samples were applied to SDS-polyacrylamide gel electrophoresis
(PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon-P, 0.45 µm)
(MilliporeSigma, Burlington, MA, USA). The membranes were blocked with 0.5% skim milk (nacalai
tesque, Kyoto, Japan) in tris-buffered saline with tween20 (TBST, 137 mM NaCl, 2.68 mM KCl, 25 mM
Tris (pH=7.4), 0.1% Tween20) and incubated with primary antibodies for 16 h at 4 ◦C and secondary
antibodies for 1 h at room temperature. The signals were developed with Clarity Western enhanced
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chemiluminescence (ECL) Substrate (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and detected
with a ChemiDoc imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Primary antibodies against CD44 (#5640), eIF4E (#2067), eIF4A (#2013, 2490), eIF4G (#2469),
poly(A)-binding protein 1 (PABP1) (#4992), eIF6 (#3833), and eRF3 (#14980) were obtained from Cell
Signaling Technology Inc. (Danvers, MA, USA). Primary antibodies against CD44 (#ab157107) were
obtained from Abcam (Cambridge, UK). Primary antibodies against β-actin (#A5316), glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (#MAB374), and yes-associated protein (YAP)/transcriptional
coactivator with PDZ-binding motif (TAZ) (#sc-101199) were purchased from Sigma-Aldrich Co. LLC
(St. Louis, MO, USA), MilliporeSigma (Burlington, MA, USA), and Santa Cruz Biotechnology (Santa
Cruz, CA, USA), respectively. Secondary antibodies conjugated with horseradish peroxidase were
obtained from Sigma-Aldrich Co. LLC (St. Louis, MO, USA).
2.7. Immunoprecipitation
Immunoprecipitation was performed as previously described [18] with modification. Briefly,
the cells were lysed in cell lysis buffer supplemented with cOmplete Protease Inhibitor Cocktail
and PhosSTOP phosphatase inhibitor cocktail. The lysate was passed through a 23G needle syringe
10 times and centrifuged at 15,000 rpm, at 4 ◦C, for 10 min. After the measurement of the protein
concentration, the supernatant was pre-cleaned with protein G sepharose (GE Healthcare Life Sciences,
Boston, MA, USA) and added with BSH compounds (BSH or BSH-polyR, the final concentration was
20 µM each). The mixture was incubated at 4 ◦C for 1 h, and we further added primary antibody against
BSH (the final concentration was 10 µg/mL) and incubated at 4 ◦C for another hour. Then, the protein
G sepharose was added to the mixture, and pull-down procedures were performed according to
the manufacturer’s recommendation. The precipitates were boiled in 1× SDS sample buffer at 95 ◦C for
5 min. After centrifugation at 15,000 rpm for 10 min, the supernatants were applied to Western blotting.
To measure the 10B concentration in the immunoprecipitates with anti-CD44 antibody from
the mixture of cell lysates and BSH compounds, the immunoprecipitates were obtained as written
above with anti-CD44 antibody (1:50, as recommended by Cell Signaling Technology Inc. (Danvers,
MA, USA)), instead of anti-BSH antibody. The precipitates were boiled in HNO3 at 95 ◦C for 5 min
and centrifuged at 15,000 rpm for 10 min. Then, the supernatants were measured using inductively
coupled plasma-atomic emission spectrometry (ICP-AES).
2.8. X-ray Irradiation and Sphere Formation Assay
For X-ray irradiation, the cells were trypsinized and resuspended in N-2-hydroxy
ethylpiperazine-N-ethanesulfonic acid (HEPES)-buffered DMEM/F-12 (FUJIFILM Wako Pure Chemical
Corporation, Osaka, Japan) supplemented with BIT 9500 and antibiotics, and irradiated at 125 keV,
15 mA to give a dose rate of 0.85 Gy/min using a Hitachi X-ray source (MBR-1520R-3) (Hitachi Ltd.,
Tohyo, Japan). After irradiation, the cells were briefly centrifuged, resuspended in normal DMEM/F-12
medium, and seeded on ultra-low attachment 24-well plates (#3473) (Corning Inc., Corning, NY, USA)
for a sphere formation assay (1000 cells/1.5 mL/well). The numbers of spheres (diameter >100 µm)
were counted 1 week after seeding.
2.9. Neutron Irradiation
In vitro testing was performed by using the Nagoya University Accelerator-Driven Neutron
Source (NUANS)*, in which neutrons are generated using a Dynamitron accelerator and a sealed Li
target [24,25]. The Dynamitron is a DC accelerator with a maximum accelerating voltage of 2.8 MV
and a maximum proton current of 15 mA. This system can generate epi-thermal neutrons of 109 n/cm2/s
at the extraction port satisfying the neutron specifications for BNCT indicated in The International
Atomic Energy Agency (IAEA) TECDOC-1223**. In the neutron irradiation experiment, a water
phantom (20cm × 20cm × 20cm) was set in front of the extraction port to produce thermal neutrons
for the neutron irradiation to cells in a micro tube. The thermal neutron flux at the irradiation
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point was measured by the gold-foil activation method and evaluated to be 6.5x 107 n/cm2/s in
the experiment. When the concentration of boron was 50 ppm in the cell, the boron dose on the cell was
estimated at approximately 3.3 Gy-eq/h. We also confirmed that a gamma ray was less than 0.5 Gy/h in
the irradiation field.
2.10. Gene Expression Analyses
The Cancer Genome Atlas (TCGA) dataset analyses were done in the UCSC Xena data browser
(https://xenabrowser.net). The expression levels of SLC7A5, CD44, EIF4E, EIF4A1, EIF4G1, and GSPT1
(which encode LAT1, CD44, eIF4E, eIF4A, eIF4G, and eRF3 proteins, respectively) were constructed
as a heat map. We obtained the CD44 and SLC7A5 expression data of glioma tissues and normal brains
from the REMBRANDT glioma dataset via betastasis (http://www.betastasis.com). The expression
levels are shown in box-plot graphs.
3. Results
3.1. Cellular Uptake of BSH-polyR in Various Types of Cancers
Although early clinical studies in the 1960–1970s were not fully convincing, we believe that BSH
has promising potential as a 10B agent for BNCT, due to its high boron content and positive data in recent
clinical studies [9]. To improve the poor membrane permeability of BSH, we previously developed
BSH-polyR (Figure 1A). Immunofluorescent analysis showed that BSH-11R, as well as BSH-3R,
successfully passed through the plasma membrane of U251 glioma cells at 20 µM, while BSH could
not (Figure 1B). As we sought to expand the possibility of BSH-polyR usage not only in glioma
but also in other kinds of cancer, including breast cancer and pancreatic cancer, we asked whether
BSH-polyR could penetrate the membrane of these types of cancer cell lines. We treated glioma cells
(U87MG and U251MG), breast cancer cells (MCF7 and MDA-MB-231), and pancreatic cancer cells
(CFPAC1 and PANC1) with BSH-11R at 10 µM for 24 h. We noticed that the efficiency of BSH-11R
penetration was different among cell lines; U87MG, U251MG, MDA-MB-231, and PANC1 demonstrated
BSH-11R uptake, but MCF7 and CFPAC1 did not (Figure 1C). This observation motivated us to identify
the primary target molecules or the determinants of the enhanced uptake, as such information would
help us select suitable patients for BSH-polyR-based BNCT in the future.
PolyR consists of serial arginine amino acids, typically between 3 and 12, and it confers cell
membrane permeability on a wide variety of molecules such as proteins, peptides, and chemicals. This
functional peptide originated from the discovery of the human immunodeficient virus (HIV)-derived
TAT peptide (RRRQRRKKRG) [26]. The TAT-mediated cellular uptake of molecules by macropinocytosis
requires a lipid raft [27,28], which consists of dense cholesterol and provides the scaffold for receptors,
adhesion proteins, anchoring proteins, and certain types of glycoproteins [29–31]. The requirement
of a lipid raft for macropinocytosis could be explained by the electrostatic interaction between
the positively charged TAT peptide and negatively charged proteoglycan/glycoproteins localized on
the lipid raft [27]. Past studies identified several candidates for the biding proteins of CPP. For example,
Futaki and colleagues identified CXCR4 as a receptor that stimulated the macropinocytic uptake of
12R, but not 8R [17]. Yet, to our knowledge, no study has identified the universal determinants of
the macropinocytosis of polyR (either short or long).
To seek the cell-surface target that determines the efficiency of BSH-polyR uptake, we focused
on the difference between MCF7 and MDA-MB-231 (Figure 1C). MDA-MB-231 cells show post-EMT
(epithelial–mesenchymal transition) and cancer stem cell-related traits: tumorigenic and metastatic
potentials [32]. Human breast cancer stem cells are molecularly defined as a population of
CD24Low/CD44High cells [33]. CD44 is a cell-surface protein that interacts with hyaluronic acid and is
involved in cell adhesion, migration, and metastasis [34–36]. Importantly, CD44 was reported to
localize at lipid rafts on the cell surface [37,38] and exhibits several types of modifications including
glycosylation [39,40]. Therefore, we examined the simple hypothesis that CD44 is a cell-surface target
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molecule of polyR. Consistent with this, the enhanced uptake of BSH-polyR observed in immunofluorescent
analysis correlated with the Western blotting pattern of CD44 in several cell lines (Figure 1D).
3.2. CD44 Is Required for BSH-PolyR Cellular Uptake
To test whether CD44 determined the enhanced cellular uptake of BSH-PolyR, we performed
a loss-of-function study. We infected U87MG glioma cells with pLKO.1-puro lentiviruses carrying
a negative-control shRNA or two different sequences of short hairpin RNA (shRNA) against human
CD44. After 2 days of infection, the cells were selected with 1 µg/mL of puromycin for 2 days.
The knockdown efficacy was validated with a Western blotting analysis (Figure 2A). Then, the selected
cells were treated with 20 µM of BSH-3R or BSH-11R in DMEM with 10% FBS and antibiotics for 24 h,
followed by immunofluorescent analysis using an anti-BSH antibody. BSH-3R appeared less efficient
for the intracellular delivery of BSH than BSH-11R, but both in BSH-3R-treated and BSH-11R-treated
cells, CD44 knockdown significantly attenuated the cellular uptake of BSH (Figure 2B).
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3.3. Direct Interaction between BSH-PolyR and CD44 Cell-Surface Protein
To ask whether BSH-polyR directly binds to the CD44 protein, we performed immunoprecipitation
experiments with anti-BSH antibody. We prepared 1 mL of cell lysate of MDA-MB-231 (protein
concentration was 2000 µg/mL), which abundantly expressed CD44 protein (Figure 1C), and mixed it
with BSH or BSH-11R to a final concentration of 20µM. After 1 h of incubation at 4 ◦C, anti-BSH antibody
was added at a final concentration of 10 µg/mL and incubated for another hour at 4 ◦C. The BSH-bound
complex was precipitated with protein G sepharose and then applied to Western blotting analysis.
BSH-11R, but not BSH, successfully adsorbed the CD44 protein from the MDA-MB-231 cell lysate
(Figure 3A). We noticed that the CD44 protein that specifically bound to BSH-11R was slightly shifted
upper from the dominant CD44 band in the input samples, suggesting that the upper band represented
a modified CD44 molecule.
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Figure 3. BSH-polyR directly interacted with the CD44 cell-surface molecule. (A) The immunoprecipitation
experiment was performed with a mixture of the cell lysate of MDA-MB-231 and BSH compounds. Anti-BSH
antibodysuccessfullyprecipitatedtheCD44molecule fromBSH-11R-addedsamples, while it failed toprecipitate
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mixed with BSH compounds and immunoprecipitated with anti-CD44 antibody. (C) The Duolink assay
identified the in situ interaction of BSH-11R and CD44.
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Then, we asked whether the CD44 immunoprecipitate contained BSH molecules. To examine
this, we performed immunoprecipitation with the anti-CD44 antibodies from MDA-MB-231 cell lysate
supplemented with 20 µM of BSH or BSH-11R. The 10B content in the immunoprecipitates was analyzed
with ICP-AES. CD44 molecules efficiently adsorbed BSH-11R, but not BSH, from MDA-MB-231 cell
lysate (Figure 3B). These data indicated that BSH-11R interacted with CD44 protein in cell lysates via
the polyR peptide.
To confirm that BSH-11R bound directly to CD44 molecules on cell surfaces, we performed
Duolink assay (proximity ligation assay, PLA). This technique allowed us to visualize the in situ
molecule–molecule interactions in cells and tissues [41], and we can detect the signals only when
the two molecules are located closer than 40 nm. We treated U87MG cells with 10 µM of BSH or
BSH-11R for 30 min and immediately washed the cells with PBS twice. Then, the U87MG cells were
fixed and applied to a Duolink assay with anti-BSH and anti-CD44 antibodies. As shown in Figure 3C,
the cells treated with BSH-11R showed much stronger signals than those treated with BSH. These data
clearly showed that the 11R peptide conferred the property of CD44 interaction on BSH molecules.
3.4. BSH-11R Is Efficiently Delivered to Cancer Stem-Like Cells
As CD44 is widely accepted as one of the most reliable cancer stem cell markers in various
kinds of cancer [42,43], and because BSH-polyR directly binds to the CD44 cell-surface protein
as shown above, we thought that BSH-polyR could be a promising cancer stem cell-directed 10B
agent. To test this possibility, we prepared several cell populations with cellular heterogeneity by
transforming NMuMG cells (normal murine mammary gland epithelial cells) with oncogenic lentivirus
and YAP1-overexpressing lentivirus (Figure 4A). The NMuMG cells were transformed upon HRas
overexpression and p53 knockdown, and they acquired cancer stem cell-related properties such
as the capacity for self-renewal and anchorage-independent growth (Figure 4B).
To enhance the stemness, we further overexpressed YAP1, one of the Hippo pathway transducers,
because it was shown to stimulate the stemness and promote malignancy in various types of
cancers [44,45]. As shown in Figure 4B, YAP1 overexpression potentiated the self-renewal capacity
and CD44 protein level. We treated NMuMG-GFP (as infection control), NMuMG-HRas/shp53,
and NMuMG-HRas/shp53/YAP1 cells with BSH (2 mM) or BSH-11R (10 µM) and performed
immunofluorescent analyses using anti-BSH antibody. We observed that BSH treatment did not
show any signals in all types of cells even at high concentrations (2 mM) (Figure 4C). On the other
hand, as we expected, BSH-11R was successfully delivered into the transformed cells, especially in
YAP1-overexpressing cells (Figure 4C).
Next, we demonstrated that BSH-polyR was directed to the CD44High cancer cell population.
To do this, we utilized NMuMG-HRas/shp53 cells, because these cells exhibited heterogeneity of
the BSH staining pattern after the treatment of BSH-11R. After the separation with EDTA, the cells
were treated with 20 µM of BSH-11R for 10 min at room temperature, and they were subjected to
immunomagnetic separation with anti-BSH antibody and the EasySep “Do-It-Yourself” selection kit.
As we expected, the positively isolated cells showed abundant expression levels of CD44 (Figure 4D).
These cells were enriched with TAZ, the other Hippo transducer essential for the maintenance of stem
cells in breast cancer [32]. Consistent with this, the positively isolated cells formed greater numbers
of spheres compared to the negative cell population (Figure 4E). These results demonstrated that
BSH-11R selectively and specifically targeted CD44High cancer cells, which was usually overexpressed
in cancer stem cells of various types of cancer.
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CD44 and TAZ and the capacity for self-renewal.
3.5. BSH-PolyR-Based BNCT Is Effective against CD44High Glioma Stem-Like Cells
We next sought to examine the anti-cancer effects of BSH-polyR-based BNCT against CD44High
cancer cells. As a model of this examination, we chose glioblastoma, because this disease was one of
the most malignant tumors that required therapeutic innovation, and we believed that BNCT was one
of the potential therapeutics as reported in the past study [9]. We prepared four types of glioblastoma
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stem-like cells, MGG4, MGG8, MGG18, and MGG23, and we first analyzed the expression levels
of CD44 (Figure 5A). Among them, we selected MGG4 and MGG18 as CD44Low and CD44High cell
models, respectively. We treated these cells with 20 µM of BSH or BSH-11R for 24 h, performed
immunofluorescent analysis, and measured the 10B concentration. BSH-11R was taken up by MGG18
cells, but not MGG4 cells (Figure 5B), and this was confirmed by ICP-MS analysis (Figure 5C).
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Figure 5. BSH-11R-based boron neutron capture therapy (BNCT) was effective against CD44High
glioma stem-like cells. (A) The CD44 profile of glioma stem-like cells. (B,C) BSH-11R was efficiently
delivered into MGG18 cells. (D) The radiosensitivity of MGG4 and MGG18 cells. The MGG18 cells
were highly resistant against X-ray irradiation. (E) BSH-11R-based BNCT induced remarkable cell
death only in MGG18 cells.
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Before we examined the effect of BSH-polyR-based BNCT, we checked the radioresistance of
these cells. To do this, we irradiated the cells using an X-ray source (MBR-1520R-3) (Hitachi Ltd.,
Tohyo, Japan) at serial doses of 0, 2, 4, 6, 8, and 10 Gy (dose rate = 1.0 Gy/min), in HEPES-buffered
culture medium. After irradiation, the cells were seeded on ultra-low attachment 24-well plates to test
the capability of anchorage-independent growth (1000 cells/1.5 mL/well). After 1 week of irradiation,
we counted the numbers of spheroids (diameter >100 µm) and calculated the ratio (normalized with
the number of spheroids at 0 Gy). X-ray irradiation readily killed MGG4 cells, but not MGG18,
suggesting that MGG18 cells were highly radioresistant (Figure 5D).
We performed BNCT experiments with these cells and BSH compounds. We predicted that
BSH-11R, but not BSH, would efficiently kill the MGG18 cells after neutron irradiation, while the MGG4
cell viability was not affected due to the lack of CD44 expression. As a neutron source, we prepared
a sealed lithium target and a DC accelerator system (Dynamitron, maximum proton energy is 2.8 MeV)
at Nagoya University. After treatment of the cells with BSH compounds for 24 h, we irradiated the cells
with the accelerator-driven neutron at a flux of 6.5 × 107 n/cm2/s. We confirmed that the gamma ray
dose was less than 0.5 Gy/h during the experiment.
After BNCT, the cells were seeded on ultra-low attachment plates and evaluated as done in the X-ray
experiment. As we expected, the pretreatment of BSH-11R and neutron irradiation significantly induced
cell death only in MGG18 (CD44High), not in MGG4 (CD44Low) (Figure 5E). These results clearly showed
that BSH-11R could be a promising 10B agent for BNCT against CD44High cancer cells. In MGG4
cells, which were highly radiosensitive (Figure 5D), no cytotoxic effect was observed after the neutron
irradiation, suggesting that our neutron source was almost free from undesirable gamma rays.
3.6. Intracellular Target of BSH-11R
Next, we sought to identify the intracellular targets of polyR, as such information would help
us to understand the intracellular distribution and retention capacity of polyR-conjugated molecules,
which might further contribute to the therapeutic optimization of BSH-polyR-based BNCT. As shown
in Figure 1, the penetrated BSH-polyR showed the cytoplasmic distribution as well as remarkable
localization at the nucleoli rather than the nucleus. This observation prompted us to examine
the relationship between BSH-polyR and RNA-related components, because the nucleoli were recently
thought of as a site of ribosomal assembly and translation [46,47].
To examine the possibility of the interaction, we performed immunoprecipitation from
the pre-cleaned lysate of U251 cells, the same as done in Figure 3A; then, we performed Western blotting
using antibodies for the translation-related components. We found that BSH itself had a binding
capacity with poly(A)-binding protein 1 (PABP1), which bound to the 3′ poly(A) tail of mRNA and thus
controlled the translational efficiency (Figure 6A). We found that the polyR peptide precipitated
translation initiation factors (eIF4E, eIF4A, eIF4G, and eIF6) and translation termination factor eRF3
(Figure 6A).
To ask whether these interactions were dependent on the RNA molecules, we incubated
the pre-cleaned cell lysate with or without 10 µg/mL of RNase A for 1 h at room temperature;
then, we performed immunoprecipitation and Western blotting. We revealed that BSH bound to
PABP1 in the presence of RNA, while polyR-addition slightly contributed to the interaction (Figure 6B).
We found that little eIF4G was pulled-down with BSH in the presence of RNA, likely via an indirect
interaction through PABP1, which were known to be bound to eIF4G. EIF4G bound with BSH-polyR in
the presence or absence of RNA, suggesting that the interaction was given by polyR (Figure 6B).
EIF4A did not bind to BSH in the presence or absence of RNA, but it bound to polyR, whose
interaction was strengthened in the absence of RNA (Figure 6B). ERF3 did not bind to BSH, but it bound
to polyR (Figure 6B). These interactions were further validated by a Duolink assay on U251 cells treated
with 20 µM of BSH-11R for 24 h. As shown in Figure 6C, the combinations of anti-BSH/anti-PABP1
and anti-BSH/anti-eIF4G gave positive Duolink signals, which were not detected in the negative
control samples.
Cells 2020, 9, 2149 14 of 20Cells 2020, 9, x FOR PEER REVIEW 15 of 22 
 
 
Figure 6. BSH-11R bound to the translation-related proteins. (A) BSH interacted with poly(A)-biding 
protein 1 (PABP1) and polyR allowed BSH to bind with the translation initiation factors and 
termination factor. (B) The interaction between PABP1 and BSH was RNA-dependent. The 
BSH-polyR interactions of eIF4A, eIF4G, and eRF3 appear dependent on the polyR part. (C) A 
Duolink assay confirmed the in situ interactions between BSH-11R and PABP1 or eIF4G in U251MG 
cells. 
To ask whether these interactions were dependent on the RNA molecules, we incubated the 
pre-cleaned cell lysate with or without 10 µg/mL of RNase A for 1 h at room temperature; then, we 
performed immunoprecipitation and Western blotting. We revealed that BSH bound to PABP1 in 
the presence of RNA, while polyR-addition slightly contributed to the interaction (Figure 6B). We 
found that little eIF4G was pulled-down with BSH in the presence of RNA, likely via an indirect 
interaction through PABP1, which were known to be bound to eIF4G. EIF4G bound with BSH-polyR 
in the presence or absence of RNA, suggesting that the interaction was given by polyR (Figure 6B). 
EIF4A did not bind to BSH in the presence or absence of RNA, but it bound to polyR, whose 
interaction was strengthened in the absence of RNA (Figure 6B). ERF3 did not bind to BSH, but it 
bound to polyR (Figure 6B). These interactions were further validated by a Duolink assay on U251 
cells treated with 20 µM of BSH-11R for 24 h. As shown in Figure 6C, the combinations of 
anti-BSH/anti-PABP1 and anti-BSH/anti-eIF4G gave positive Duolink signals, which were not 
detected in the negative control samples. 
3.7. Molecular Properties of BSH-PolyR Define the Intracellular Retention Time of BSH-PolyR 
We discovered that BSH was capable of binding to PABP1, and polyR to eIF4G, eIF4A, and 
eRF3. To ask whether the binding properties of polyR depended on the length of arginine peptides, 
we performed a similar immunoprecipitation experiment with 20 µM of BSH, BSH-3R, and BSH-11R. 
Figure 6. BSH-11R bound to the translation-related proteins. (A) BSH interacted with poly(A)-biding
protein 1 (PABP1) and polyR allowed BSH to b nd with the translation initiation factors and termination
factor. (B) The interaction between PABP1 an BSH was RNA-dependent. The BSH-polyR interacti n
of eIF4A, eIF4G, and eRF3 appear dependent on the polyR part. (C) A Duolink as ay confirmed the in
situ interactions between BSH-11R and PABP1 or eIF4G in U251MG cells.
3.7. Molecular Properties of BSH-PolyR Define the Intracellular Retention Time of BSH-PolyR
We discovered that BSH was capable of binding to PABP1, and polyR to eIF4G, eIF4A, and eRF3.
To ask whether the binding properties of polyR depended on the length of arginine peptides, we
performed a similar immunoprecipitation experiment with 20µM of BSH, BSH-3R, and BSH-11R. We did
not observe a significant difference of eIF4G biding to BSH or BSH-3R, but we did observe an increase of
the binding to BSH-11R (Figure 7A). We found that PABP1 bound to BSH in an RNA-dependent manner,
and the capability of the binding to BSH compounds depended on the length of polyR (Figure 7A). We
showed that eRF3 bound to arginine peptides but not BSH, an the affinity to BSH-polyR increased
as the polyR length extended (Figure 7A). These data clearly showed that the polyR-peptide affected
the binding capacity of BSH compounds and translation-related proteins.
Next, we examined whether the polyR length affected the intracellular retention time of BSH-polyR.
To do this, we treated U251MG cells with 20 µM of BSH-3R or BSH-11R for 24 h and left them in culture
medium without BSH compounds for 1 and 8 h. As shown in Figure 7B, although the starting amounts
of intracellular BSH were different, the signals became invisible after 8 h in BSH-3R-treated cells, hile
they were still detected in BSH-11R-treated cells.
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3.8. Bioinformatics Analyses
Thus far, we ide tified CD44 and the compo ents of translational machinery as the cell-surface
and intracellular targets of BSH-polyR, respectively. We propose that these properties would be helpful
for selecting patients. Indeed, in the REMBRANDT brain cancer dataset, for example, the expression
levels of CD44 were increased in most glioblastoma (GBM) cases, but they were kept lower in normal
brain tissues (Figure 8A). On the other hand, the expression levels of SLC7A5 (encodes LAT1 amino acid
transporter, which is responsible for the BPA uptake) in GBM, as well as in the other types of tumors,
were almost the same as those in normal brain tissues (Figure 8B). Of note, in some cases of GBM,
the expression levels of SLC7A5 appeared to be lower than the normal brain. Interestingly, in the TCGA
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(The Cancer Genome Atlas) GBM dataset, we realized that the patients with a CD44High signature
tended to show higher expressions of the genes that encoded the proteins of the intracellular targets of
BSH-polyR (eIF4E, eIF4A, eRF3, and eIF4G) (Figure 8C). This might be favorable for the intracellular
retention of BSH-polyR and therapeutic optimization. Although in vivo studies using appropriate
tumor models are warranted in the future, these data suggest a potential of BSH-polyR as a boron
delivery agent for BNCT.Cells 2020, 9, x FOR PEER REVIEW 18 of 22 
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the expression levels of SLC7A5 in brain tumor samples and normal brains. (C) Patients with high CD44
expression levels tended to harbor high expression levels of the genes encoding translation-related
proteins. (D) Profiles of the expression levels of CD44 and SLC7A5 in the The Cancer Genome Atlas
(TCGA) glioblastoma (GBM) dataset.
4. Discussion
In this study, we defined the cell-surface and intracellular targets of BSH-polyR. We identified
CD44 as one of the critical determinants of BSH-polyR uptake and revealed that BSH-polyR directly
bound to the CD44 molecule, using biological and biochemical techniques (Figures 2 and 3). Consistent
with this, BSH-polyR was readily penetrated into CD44-expressing cells, whose properties were similar
to those of cancer stem-like cells (Figure 4). As a proof of principle, we performed BSH-polyR-based
BNCT against the glioblastoma stem-like cells MGG4 and MGG18. BSH-polyR was successfully
delivered into MGG18 (CD44High) but not MGG4 (CD44Low), and it thereby induced BNCT-dependent
cell death specifically in MGG18 cells (Figure 5).
Based on the immunofluorescent finding of BSH-polyR distribution to nucleoli, we further
investigated the intracellular targets of BSH-polyR and identified translational machinery-related
proteins including eIF4G, eIF4A, eRF3, and PABP1 (Figure 6). Intriguingly, BSH was shown bound
to PABP1 in an RNA-dependent manner, while the other proteins were shown to interact with
the polyR peptide. The affinity of BSH-polyR for the proteins was dependent on the length of arginine
and accordingly determined the intracellular retention time after treatment with BSH-polyR (Figure 7).
The translation-related proteins as the intracellular targets of BSH or BSH-polyR suggested that
BSH-based BNCT might induce selective damage to the translational machinery, which was recently
proposed as a target for anti-cancer drug development [48,49]. Indeed, in the BNCT experiment in
this study, we observed efficient cell death in MGG18 cells treated with BSH-polyR. This suggests that
BSH-polyR-based BNCT can induce cell death in a different way from that usually is associated with
X-ray irradiation.
By analyzing the expression levels of the BSH-polyR targets in a clinical dataset, we suggest
that BSH-polyR might be suitable for certain types of malignant tumors. For example, in GBM,
BSH-polyR appeared tumor-selective, because CD44 expression was not typically detected in normal
brain. Importantly, BSH-polyR might be useful to treat the patients with low expression levels of
SLC7A5, which indicates that they are not candidates for BPA-BNCT. On the other hand, BPA might be
suitable for the patients with low expression levels of CD44, which would indicate that BSH-polyR
would not be a suitable boron delivery agent (Figure 8). To expand the possibility of BNCT and to
accelerate the establishment of standardized medicine in the BNCT field, we need to develop novel
boron agents that have different properties from BPA.
5. Conclusions
In the present study, we have defined the molecular properties of BSH-polyR and identified
the cell-surface and intracellular targets of BSH-polyR. BSH-polyR directly binds to the CD44 cell-surface
molecule for cellular uptake. Once penetrated, BSH-polyR interacts with translation-related proteins via
BSH or polyR parts. As a potential boron delivery agent, we validated that BSH-polyR was effective in
BNCT against CD44High tumor cells. We showed that the molecular definition of the BSH-polyR-binding
proteins might contribute to therapeutic optimization in the future.
6. Patents
A.F. is the inventor of the patent of “Cancer lesion tissue evaluation for optimizing effect of boron
neutron capture therapy” (WO/2019/160129).
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